IMIDOMICS, ESTABLECIMIENTO PERMANENTE EN ESPANA
Plaça Sant Gregori Taumaturg, 8 Planta At. Pta. 2 08021 Barcelona
http://imidomics.com
Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs).
Capital
Investors: Bristol-Myers Squibb, Tao Capital Partners,DNS Capital,The Pritzker Organization
Source: Press releases newsletters & platforms company websites annual reports & accounts regulatory body sites & stock exchanges